Remove 2013 Remove Acquisition Remove Blogging Remove Pricing
article thumbnail

Despite Low Crop Prices, Corporate and VC Agtech Investments Soar

Xconomy

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. The increase in dollars flowing to agtech comes despite commodity prices that are down 65 percent from their 2013 peak, the report says.

article thumbnail

As Populist as it May Feel, 98% of VCs Aren’t Dumb

Both Sides of the Table

In 2013 it is expected to be around $35 billion. Compare the state of play in 2013 versus 15 years ago. 2013 = $25 billion of which Apples stage is more than $8 billion at > 90% gross margin. So I prefer to watch what works first and pay a higher price to get in when it’s proven.” hours / day.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evoke Pharma’s Stock Sinks on Stomach Drug’s Phase 3 Failure

Xconomy

In early trading Monday, Evoke’s (NASDAQ: EVOK ) stock price was down 72 percent to $3.02 Actavis is now known as Allergan (NYSE: AGN ), adopting the name following its acquisition of that company last year. per share as of 11:30 a.m. in New York. Others have had trouble developing a treatment for diabetic gastroparesis, too.

Study 40
article thumbnail

CreatorUp Links You With Top Filmakers & YouTube Creators To Make Awesome Web Series

Tech Zulu Event

CreatorUp was launched online in Beta in January of 2013 and our startup team is based in Los Angeles. Mike’s work in sales, marketing, distribution, and business development is essential to customer acquisition, growth, and scalability. TechZulu caught up with the founder Mike Tringe and this is what he told us. Who are its founders?

Web 93
article thumbnail

With Biogen at a Crossroads, CEO Scangos to Step Down

Xconomy

After a year in which Biogen’s share price has fallen by more than a third and one of its top drug prospects failed, Scangos, who has led the company since 2010, has announced plans to step down. Biogen has been very deliberate in its dealmaking, reluctant to make a big splash with a large acquisition. [ Updated, 9:20 a.m.

article thumbnail

Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More

Xconomy

Celgene paid Acetylon $100 million in 2013 for an option to buy the company outright, but the deal recently expired without an acquisition, leaving Acetylon to chart a new course. Celgene remains an Acetylon investor, however, and the two are testing drugs together in a variety of trials. In the U.S.,

Google 40
article thumbnail

Let’s Get Weird, a SXSW Interactive Recap (2014)

Tech Zulu Event

As we know, long gone are the days of experiencing SXSW Interactive with just 9,000 other tech entrepreneurs and business brights – with 30,000 registrants in 2013 and the final numbers for 2014 still in the works. Erin Chase – Favado , combining price comparisons with grocery shopping.